

Outlook For Global Medicines Through 2021 Iqvia

When people should go to the books stores, search inauguration by shop, shelf by shelf, it is in point of fact problematic. This is why we provide the ebook compilations in this website. It will categorically ease you to look guide **outlook for global medicines through 2021 iqvia** as you such as.

By searching the title, publisher, or authors of guide you in reality want, you can discover them rapidly. In the house, workplace, or perhaps in your method can be all best place within net connections. If you direct to download and install the outlook for global medicines through 2021 iqvia, it is enormously simple then, past currently we extend the connect to buy and make bargains to download and install outlook for global medicines through 2021 iqvia in view of that simple!

History of Biology and Medicine Series: TB, the invisible Global Health Emergency

Meet Annie Martin, Global Head of Precision Medicine **Global Warming: Fact or Fiction? Featuring Physicists Willie Soon and Elliott D. Bloom** *The Mystery of Fast-5 and D.I.E.T.: Bert Herring, MD at TEDxRiversideAvondale* ~~A Bitter Pill: Assuring the Quality, Safety, and Affordability of Generic Medicines~~

The Big Picture: Global Biodiversity Outlook - Target 30x30 ~~Why Drugs Are So Expensive~~ Medicines Safety in Singapore *Medicine pricing in the UK* **Taking a Break from Renovations (she left me alone for 72 hours) Amsterdam VLOG** ~~Garage Clear Out Global Market Access Webinar - 9 May 2019~~ ~~Interaction with Prof Joseph Stiglitz on Global Economic Outlook~~ **Revealing the Mind: The Promise of Psychedelics** **Bottle of Lies: How Poor FDA Oversight** ~~Fraud in Generic Drug Industry Threaten Patients' Health~~ *Introduction to Traditional Chinese Medicine by David Miller MD, LAc* **Coronavirus drug abuse: A pandemic within a pandemic? | COVID-19 Special** ~~Employees in Global Medicines Development and Medical Affairs (GDMA) Talk About the Future of Vertex~~ ~~Why you can't get the lifesaving drugs you need | Ellen 't Hoen | TEDxZurich~~ Professor David Nutt - 'Not all in the mind' public lecture

Fake Medicines Pose Global Danger *Outlook For Global Medicines Through*

The global outlook for medicine use and spending affects the prospects of life sciences companies, insurers and the health of populations around the world. This report includes the latest predictions for the global pharmaceutical market along with geographic, therapy area and channel perspectives. It assesses the impact of new drug launches, biosimilars, and growth in the use of specialty medicines.

The Global Use of Medicine in 2019 and Outlook to 2023 - IQVIA

Global medicine spending will reach nearly \$1.5 trillion by 2021 on an invoice price basis, up nearly \$370 billion from the 2016 estimated spending level. Importantly for the outlook is that spending growth is slowing in 2016, declining from nearly 9 per cent growth in 2014 and 2015 to just 4–7 per cent CAGR over the next five years.

Outlook for global medicines through 2021 - Express Pharma

Global Spending on Medicines 4 Global spending on medicines Total global spending will reach \$1.3Tn in 2018, an increase of \$290-320Bn from 2013, driven by population growth, an aging population, and improved access in pharmerging markets. • Of developed markets, the U.S. will see the largest per capita spending increase from 2013 to 2018,

Global Outlook for Medicines Through 2018

Get Free Outlook For Global Medicines Through 2021 Iqvia

Global Outlook for Medicines Through 2018. Report by the IMS Institute for Healthcare Informatics. Global Spending on Medicines • Spending on medicines globally is expected to reach nearly \$1.3Tn by 2018. • Using actual and forecast exchange rates, the absolute global spend for pharmaceuticals will change by \$290-320Bn, compared to \$194Bn in

Global Outlook for Medicines Through 2018 - SEFAP

By the numbers • Global medicine spending will reach nearly \$1.5 trillion by 2021 • Growth will slow from nearly 9% in 2014 and 2015 to 4–7% over the next five years • Hepatitis C treatments which drove 2–3% points of growth in 2014 and 2015 will have a reduced impact to 2021 • Oncology, autoimmune and diabetes treatments will drive much of the growth • The U.S. will continue as the world's largest pharmaceutical market and pharmerging markets will make up 9 of the top 20 ...

QIMS Outlook for Global Medicines through 2016-2021

Outlook-For-Global-Medicines-Through-2021-Iqvia 2/3 PDF Drive - Search and download PDF files for free. Oct 2017- Outlook for Global Medicines through 2021 Global pharma spending and growth 2007 -2022 0% 2% 4% 6% 8% 10% 12% 0 200 400 600 800 1,000 1,200 1,400 1,600

Outlook For Global Medicines Through 2021 Iqvia

Global growth of medicine spending through 2023 will primarily be driven by developed markets and their adoption of a wave of newly launched innovative products.

JANUARY 2019 The Global Use of Medicine in 2019 and ...

Global medicine use and drivers of growth. Global spending on medicines will reach nearly \$1.5 trillion in 2021 growing at 4–7 %—only slightly slower than the 5.9% growth over the past five ...

December 2016 - Morning Consult

Spending on medicines has increased everywhere globally. However, the United States takes the lead in total medicines spending globally and is expected to remain the top country for medicines...

Global spending on medicines 2024 forecast | Statista

Global spending on medicines will reach \$1.4 trillion by 2020, an increase of 29-32% from 2015 compared to an increase of 35% in the prior 5 years. Spending will be concentrated in developed markets, with more than half for original brands and focused on non-communicable diseases.

November 2015 Global Medicines Use in 2020 - IQVIA

In absolute terms, global spending on prescription medicines will increase by \$205-\$235Bn in the five years to 2017, reaching over \$1 trillion. The level of increase is comparable to the \$234Bn by...

The Global Use of Medicines: Outlook through 2017

Pharmaceutical spending data are from QuintilesIMS Institute (2016), "Outlook for Global Medicines through 2021," December 2016. Population and income (gross domestic product) data are from the...

The global burden of medical innovation - Brookings

Get Free Outlook For Global Medicines Through 2021 Iqvia

Global medicine spending will reach nearly \$1.5 trillion through 2021 on an invoice price basis, rising 4-7 percent CAGR. Growth in spending will slow from nearly 9 percent in 2014 and 2015—a...

QuintilesIMS Institute Forecast: Global Drug Market Will ...

You have remained in right site to begin getting this info. get the outlook for global medicines through 2021 iqvia belong to that we meet the expense of here and check out the link. You could purchase guide outlook for global medicines through 2021 iqvia or acquire it as soon as feasible.

[MOBI] Outlook For Global

The report, Outlook for Global Medicines Through 2021: Balancing Cost and Value, found annual spending growth is expected to rebalance. (Images: iStock/michaelquirk) Total spending on medicines is expected to reach \$1.5 trillion by 2021, up 33% from 2016 – with historical amounts of new medicines emerging from the pipeline, according to a recent report by QuintilesIMS Institute.

QuintilesIMS Institute: global drug market to reach \$1.5tn ...

now is outlook for global medicines through 2021 iqvia below. To provide these unique information services, Doody Enterprises has forged successful relationships with more than 250 book publishers in the health sciences ...

Outlook For Global Medicines Through 2021 Iqvia

Description Sanofi Flashcards on QuintilesIMS Institute 2016: Outlook for Global Medicine through 2021, created by Shane Naki on 11/01/2017.

QuintilesIMS Institute 2016: Outlook for Global Medicine ...

Global Market Spending, based on list price, to grow 3-6% in value in the next five years
Source: IQVIA Market Prognosis, Sept 2017; IQVIA Institute, Oct 2017- Outlook for Global Medicines through 2021 Global pharma spending and growth 2007 -2022 0% 2% 4% 6% 8% 10% 12% 0 200 400 600 800 1,000 1,200 1,400 1,600

Prescription medicines trends: an overview and perspective ...

The outlook for medicine spending through 2021 is for mid-single digit growth driven by further clusters of innovative treatments, offset by a rising impact from brands facing generic or biosimilar competition.

The history of patent harmonization is a story of dynamic actors, whose interactions with established structures shaped the patent regime. From the inception of the trade regime to include intellectual property (IP) rights to the present, this book documents the role of different sets of actors – states, transnational business corporations, or civil society groups – and their influence on the structures – such as national and international agreements, organizations, and private entities – that have caused changes to healthcare and access to medication.

Presenting the debates over patents, trade, and the Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS Agreement), as it galvanized non-state and nonbusiness actors, the book highlights how an alternative framing and understanding of pharmaceutical patent rights emerged: as a public issue, instead of a trade or IP issue. The book thus offers an important analysis of the legal and political dynamics through which the contest for access to

lifesaving medication has been, and will continue to be, fought. In addition to academics working in the areas of international law, development, and public health, this book will also be of interest to policy makers, state actors, and others with relevant concerns working in nongovernmental and international organizations.

Protecting and promoting health is inherently a political endeavor that requires a sophisticated understanding of the distribution and use of power. Yet while the global nature of health is widely recognized, its political nature is less well understood. In recent decades, the interdisciplinary field of global health politics has emerged to demonstrate the interconnections of health and core political topics, including foreign and security policy, trade, economics, and development. Today a growing body of scholarship examines how the global health landscape has both shaped and been shaped by political actors and structures. The Oxford Handbook of Global Health Politics provides an authoritative overview and assessment of research on this important and complicated subject. The volume is motivated by two arguments. First, health is not simply a technical subject, requiring evidence-based solutions to real-world problems, but an arena of political contestation where norms, values, and interests also compete and collide. Second, globalization has fundamentally changed the nature of health politics in terms of the ideas, interests, and institutions involved. The volume comprises more than 30 chapters by leading experts in global health and politics. Each chapter provides an overview of the state of the art on a given theoretical perspective, major actor, or global health issue. The Handbook offers both an excellent introduction to scholars new to the field and also an invaluable teaching and research resource for experts seeking to understand global health politics and its future directions.

Reverse payment settlements or “pay-for-delay agreements” between originators and generic drug manufacturers create heated debates regarding the balance between competition and intellectual property law. These settlements touch upon sensitive issues such as timely generic entry and access to affordable pharmaceuticals and also the need to preserve innovation incentives for originators and to strengthen the pipeline of life-saving pharmaceuticals. This book is one of the first to critically and comparatively analyse how such patent settlements and various other strategies employed by the pharmaceutical industry are scrutinised by both United States (US) and European courts and enforcement authorities, and to discuss the applicable legal tests and the main criteria used for their assessment. The book’s ultimate objective is to provide guidance to the pharmaceutical industry regarding the types of patent settlements, strategies and conduct which may be problematic from US antitrust and European Union (EU) competition law perspectives and to assist practitioners in structuring settlements which are both efficient and compliant. To this end, an exhaustive legal analysis of some of the most controversial issues regarding pharmaceutical patent settlements is provided, including: – the lengthy split among US Circuit Courts on the issue of pay-for-delay settlements, its resolution by the US Supreme Court in *FTC v. Actavis* and subsequent jurisprudence; – the decision of *Lundbeck v. Commission* by the European General Court and the *Servier* decision of the European Commission; – the *Roche/Novartis* decision of the European Court of Justice and the most important decisions by National Competition Authorities on pharma patent settlements in the EU; – an overview of other types of strategies such as product-hopping and product reformulations, no-authorised generic commitments, problematic side-deals, mechanisms affecting generic substitution; – the rejection of the “scope of the patent” test in both the US and the EU and the balancing of patent law and antitrust law considerations in the prevailing applicable tests; – the benefits of settlements and the main criteria for assessing their legitimacy under US antitrust and EU competition law. The analysis provides concrete examples of both illegitimate and legitimate settlements and strategies, emphasising on

conduct that falls within a grey zone and on the circumstances and criteria under which such conduct could be deemed problematic from an antitrust perspective. This book will serve as a valuable guide for pharmaceutical companies wishing to minimise the risk of engaging in conduct that could potentially infringe US antitrust and EU competition law. It further aims to save courts and enforcement agencies and also practitioners and academics considerable time and resources by providing an exhaustive analysis of the relevant caselaw, with the ultimate goal to increase legal certainty on the most controversial aspects of patent settlements in the pharmaceutical industry.

This book builds upon a wide variety of academic and professional resources to offer an in-depth analysis of the nature, causes, and consequences of major business and technology trends of our time. First, prospects for energy, commodities, water, food, and healthcare services are explored. Then, leading business transformations such as the sharing economy, Fourth Industrial Revolution, gig economy, and recent developments in the global economy are analyzed. Finally, innovation and emerging technologies including automation, robotics, connectivity, quantum computing, and new materials and energies are examined and their business implications are discussed. Major Business and Technology Trends Shaping the Contemporary World is a timely and relevant reference for business leaders, managers, students, and all those who are passionate about understanding our rapidly changing world.

Botanicals, which have been part of human food and medicine for thousands of years, are perceived as being safer than synthetic pharmaceuticals. The global botanical drug market was expected to reach \$26.6 billion by 2017. In terms of FDA regulations, botanical drugs are no different from non-botanical products, having to meet the safety and effectiveness standards of a new drug in accordance. This book comprises a complete start-to-end process from drug-idea conception, to drug development process.

The pulling out of the Trans-Pacific Partnership (TPP) by the US marks a new era for trade deals and potentially for intellectual property (IP). The TPP has evolved to become the Comprehensive and Progressive Agreement for TPP (CPTPP) with the remaining 11 members suspending some of its provisions, over half of which are IP-related. While the TPP excludes the two Asian giants – India and the People's Republic of China (PRC) – the ongoing Regional Comprehensive Economic Partnership (RCEP) negotiations include both of them. The first part of this edited collection sets out to re-examine some basic principles of trade negotiation, such as choosing the right representatives to negotiate and enhancing transparency as a cure to the public's distrust against trade talks; moreover, it analyses how CPTPP might impact on RCEP's IP chapter and examines the possible norm setters of Asian IP. It then focuses on the PRC's trade and IP strategy against the backdrop of the power games between the PRC, India and the US. The second part of the book reflects on issues related to investor–state dispute settlement and its relationship with IP, such as how to re-calibrate the balance in international investment arbitration, and whether compulsory license of IP constitutes expropriation in India, the PRC and select ASEAN countries. The third part of the book questions and strives to improve some of the proposed IP provisions of CPTPP and RCEP and to redefine some aspects of international IP norms, such as: pre-grant patent opposition and experimental use exception; patent term extension; patent linkage and data exclusivity for the pharmaceutical sector; plant variety protection; pre-established damages for copyright infringement; and the restructuring of copyright limitations in the public interest.

This report reviews the important role of medicines in health systems, describes recent trends in pharmaceutical expenditure and financing, and summarises the approaches used by OECD

countries to determine coverage and pricing.

The essence of the functioning of any organization, whether commercial or non-profit, is to provide value to groups of recipients whose expectations undoubtedly change over time. Various competition mechanisms in the market apply to both business-oriented organizations and organizations operating in the sphere of public utilities. This monograph includes examples of the problems facing contemporary organizations, and at the same time provides evidence, confirmed by research results, that indicates the direction of current changes. The analysis of changes taking place in organizations was carried out in many dimensions. The content layout adopted in the monograph presents four research perspectives, where the subject of the research is the organization; the modern tools used in organization management, the impact of the market economy on organizations, and sectoral or industry aspects of the organization's functioning. In the first chapter, four studies related to commercial and non-commercial organizations have been collated. Researchers of academic organizations who in order to meet the expectations of students increase their activity in the field of entrepreneurship and their support for the most talented students. Both examples show the need to conduct research, develop knowledge about own activities, and focus on the needs of the environment. Entrepreneurial universities are open to the implementation of joint ventures with entities in their environment, which affect the development of the university, its students, as well as the entities. Entrepreneurship, which is based on the ability to take advantage of market opportunities, also creates opportunities for developing the ability to flexibly shape and adapt programs, methods and operating principles to the growing expectations of their environment. The ability to develop your potential as well as the potential of your students plays a crucial role. In the pursuit of excellence, a strong focus should be placed on talented students and the development of all possible forms of support that could determine an output of graduates with particularly high development potential. In the research presented in this monograph, the authors compare the activity of universities in the USA, the Netherlands, and Poland in the area of talent development. The comparative analysis becomes a valuable source of indicating imperfections, but also examples of potential forms of positive activity in this area. Equally important in this part of the monograph is the research on the learning organization. Through a bibliometric analysis, the author identified the fields of research on the learning organization. In addition to research areas related to various dimensions, primarily human, cultural and managerial, the types of organizations in which such research is most often conducted have been indicated. They also include the organizations of the two sectors presented: education and healthcare. The same part of the monograph also presents the results of research in the hotel sector, where the main research problem was the creation of customer value, taking into account the conditions stimulating the dynamics of the business models of hotel enterprises. Referring to business models was considered important because of the significance of decision-making patterns that help to build a competitive advantage and achieve market success by creating value for customers. The concept of creating value for customers is currently treated in cross-sectoral or industry categories and is a universal approach to managing organizations. The second chapter of the monograph presents research on the modern tools used in organization management. Concepts such as work–life balance, shaping the innovation process within the framework of decisions taken in the process, marketing communication, or the use of gamification in research and development, are examples of a wide range of relationships between today's organization and its surroundings. Finding employees, and retaining them, is also a growing challenge in developing countries, where labor supply is steadily decreasing. The expectations of employees are increasing, especially in relation to respecting the personal, non-professional side of life. Thus, it should be recognized that research on work–life balance is a developing space for organization and management

researchers. Modeling the innovation process in an organization is another research trend that is important today, especially in terms of developing competitiveness. Decision-making is one of the key components of the innovation process. This aspect, in qualitative terms, was presented in the next study in the second part of the monograph. Similarly, marketing communication is invariably an important area of research in organizations, which has evolved due to rapidly developing information technologies and, at the same time, the changing preferences of users of these technologies. The last study in this second part of the monograph relates to innovation and the use of computer games. The tools of gamification are used to shape the attitudes of individual energy consumers. The observations presented show that it is worth making attempts to use unconventional methods and tools, in this case, to develop customer knowledge and strengthen the behaviors desired in the energy market. The third chapter of the monograph is devoted to the financial aspects of the functioning of commercial and non-profit organizations in a market economy. Increasing the efficiency of public entities, specifically conditioned in economic policies and dependent on political decisions, has been the subject of numerous studies. The research study presented in the monograph refers to the relationship between financial strategies and profit management in public industrial companies listed on the Warsaw Stock Exchange. It is worth noting that no research in this field has been conducted to date in the context of the Polish capital market. The next study refers to the French market. Its purpose was to evaluate and test long-term memory in the French stock exchanges. Research results contribute significantly to explaining the lack of consensus regarding long memory in stock returns. The research covers a significant, 25-year period of operation of the Euronext platform during which 6634 observations were provided. The conclusions of the study may be particularly important for regulators and risk managers. Another study presents the results of bankruptcy risk tests for Polish and Czech logistics companies using a comprehensive classification approach. As a result of the research, a tool for risk assessment and forecasting was developed, enabling the early prediction of bankruptcy of enterprises. At the end of the third chapter of the monograph, the results of health expenditure analysis based on information provided by the Health Account System are presented. Particular attention has been focused on the programming sources of financing healthcare in new European Union countries. Socio-technical and environmental aspects of the organization are the subject of interest of researchers presenting the results of their research in the fourth chapter of the monograph. The problems of economic migration and working conditions have been the subject of interest for many years in the strongly developing trend of labor market research. The research results contained in the study relate primarily to the issues of occupational safety of Ukrainians employed in Poland. These issues are gaining importance, especially when the number of people migrating from Ukraine to Poland in search of work has been growing for several years. In the face of such a large scale of Ukrainian immigrants employed in Polish enterprises, there is still a lack of regulations protecting or securing the interests of employees and employers. The next research presentation highlights the problems of the "circular economy," which, according to the author, is developing too slowly in Poland. The research is valuable for systematizing the idea of a circular economy based on the theoretical and practical aspects of this phenomenon. The results of the analysis are also of practical importance for the process of modeling and implementing this idea in Poland. Further, the innovation paradigm of economic health and the prosperity of society is the subject of the research carried out, based on a review of the health economy considering innovation and its impact on population growth and prosperity in the world. The research particularly highlights the consequences of socio-demographic, environmental and business changes in the field of consumer goods. The socio-technical, as well as the environmental, aspects of the organization are also included in the last study presented. The purpose of this study was to identify the attitudes of IT employees in the Polish

ITC sector towards remote work. Since the effective and efficient collaboration of distributed employees performing remote work has become even more necessary for the success of projects, numerous research works are being conducted focusing on the consequences of remote work. The presented research results are an important contribution to the discussion of researchers and management practitioners. By publishing this monograph, which covers a wide spectrum of research problems in contemporary commercial and non-profit organizations, the editors and authors presenting the results of their research express a hope that they are contributing to the widespread dissemination and enrichment of knowledge and, consequently, socio-economic development.

A comprehensive overview of the new business context for biopharma companies, featuring numerous case studies and state-of-the-art marketing models Biotechnology has developed into a key innovation driver especially in the field of human healthcare. But as the biopharma industry continues to grow and expand its reach, development costs are colliding with aging demographics and cost-containment policies of private and public payers. Concurrently, the development and increased affordability of sophisticated digital technologies has fundamentally altered many industries including healthcare. The arrival of new information technology (infotech) companies on the healthcare scene presents both opportunities and challenges for the biopharma business model. To capitalize on new digital technologies from R&D through commercialization requires industry leaders to adopt new business models, develop new digital and data capabilities, and partner with innovators and payers worldwide. Written by two experts, both of whom have had decades of experience in the field, this book provides a comprehensive overview of the new business context and marketing models for biotech companies. Informed by extensive input by senior biotech executives and leading consultancies serving the industry, it analyzes the strategies and key success factors for the financing, development, and commercialization of novel therapeutic products, including strategies for engagement with patients, physicians and healthcare payers. Throughout case studies provide researchers, corporate marketers, senior managers, consultants, financial analysts, and other professionals involved in the biotech sector with insights, ideas, and models. JACQUALYN FOUSE, PhD, RETIRED PRESIDENT AND CHIEF OPERATING OFFICER, CELGENE "Biotech companies have long been innovators, using the latest technologies to enable cutting edge science to help patients with serious diseases. This book is essential to help biotech firms understand how they can—and must—apply the newest technologies including disruptive ones, alongside science, to innovate and bring new value to the healthcare system." BRUCE DARROW, MD, PhD, CHIEF MEDICAL INFORMATION OFFICER, MOUNT SINAI HEALTH SYSTEM "Simon and Giovannetti have written an essential user's manual explaining the complicated interplay of the patients who deserve cutting-edge medical care, the biotechnology companies (big and small) creating the breakthroughs, and the healthcare organizations and clinicians who bridge those worlds." EMMANUEL BLIN, FORMER CHIEF STRATEGY OFFICER AND SENIOR VICE PRESIDENT, BRISTOL-MYERS SQUIBB "If you want to know where biopharma is going, read this book! Our industry is facing unprecedented opportunities driven by major scientific breakthroughs, while transforming itself to address accelerated landscape changes driven by digital revolutions and the emergence of value-based healthcare worldwide. In this ever-changing context, we all need to focus everything we do on the patients. They are why we exist as an industry, and this is ultimately what this insightful essay is really about." JOHN MARAGANORE, PRESIDENT AND CHIEF EXECUTIVE OFFICER, ALNYLAM PHARMACEUTICALS "Since the mapping of the human genome was completed nearly 15 years ago, the biotechnology industry has led the rapid translation of raw science to today's innovative medicines. However, the work does not stop in the lab. Delivering these novel

Get Free Outlook For Global Medicines Through 2021 Iqvia

medicines to patients is a complex and multifaceted process, which is elegantly described in this new book.”

Pharmaceutical Care in Digital Revolution demonstrates how blending human and digital pharmaceutical care can establish optimal Apothecary Intelligence (AI). Organized into four parts, it examines digital health advances that will synergize the pharmaceutical care process and prepares stakeholders for a dynamic future, fueled with innovation. Beginning with the global picture on health care systems, patients' expectations, and current pharmaceutical care practices, the book covers details of relevant digital technologies as well as compliance, ethical, educational, and cultural aspects to take successful steps towards digital pharmaceutical care. The text includes links to lectures and technology facts, tutorials on how to implement advances in your own working environment, and examples of stakeholders who are successful in building synergy between digital and pharma. Pharmaceutical Care in Digital Revolution is a practical resource to equip pharmaceutical care stakeholders, such as pharmacists, physicians, pharmacy technicians, and students as well as those in surrounding ecosystems like payers or regulators. It is a crucial reference to understand how technological innovation is changing the paradigm in which we provide current and future pharmaceutical care and how to keep it accessible, affordable, and sustainable. Learn about advances in digital health technology and apply them as a change leader to create circular pharmaceutical care Provides insights on future pharmaceutical care and implement essential conditions to create the best outlook for patients Access links, QR codes, and explanatory animations as educational material to the book

Copyright code : 9d43bc225ca4dbc124c0da9a97e1d969